Bastatin

Quick links to important sections

Bastatin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bastatin

Quick Facts

Property Description
Active ingredient Atorvastatin
Form Film-coated tablets
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Managing elevated blood lipids
Origin Synthetic compound

What Type of Medicine is Bastatin? (Identity and Classification)

Bastatin is a prescription drug identified by its core active ingredient, Atorvastatin, which is classified as a synthetic compound. It belongs to the specific pharmacological class of HMG-CoA reductase inhibitors—a group of medicines widely known as Statins. This class of drug is systematically used to reduce high levels of cholesterol and other fats in the blood. Bastatin is a clinically recognized systemic agent utilized for regulating fat metabolism in the bloodstream, supporting its essential role as a lipid-lowering agent.

The Composition and Form of Bastatin (Structure and Origin)

The core chemical entity is Atorvastatin, typically provided as the single-active-component salt, Atorvastatin calcium trihydrate. This substance is formulated as a single-ingredient product in the standard oral dosage form of a film-coated tablet. Atorvastatin is characterized by a potent and highly selective action on liver cells. This selectivity is a key feature that distinguishes Atorvastatin as a highly optimized molecule within the Statin class, designed for targeted metabolic intervention.

The General Purpose of Bastatin (High-Level Benefit)

The fundamental purpose of Bastatin is to manage and lower elevated levels of fats in the blood, primarily focusing on reducing low-density lipoprotein (LDL) cholesterol. This reduction is achieved through the drug's mechanism of competitively inhibiting the enzyme HMG-CoA reductase in the hepatocytes (liver cells), thereby limiting the liver’s internal synthesis of cholesterol. For example, a common application is its use in adults who require control of their cholesterol levels as part of a long-term therapeutic strategy. This action confirms its role as a fundamental lipid-lowering agent used to promote a healthier lipid balance for approved patient populations.

Regulatory References

  1. Atorvastatin (StatPearls) - NIH

What side effects are possible with Bastatin?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse reactions and safety characteristics of Atorvastatin (the active ingredient in Bastatin), as classified by regulatory authorities such as the EMA and FDA. This section focuses strictly on the safety profile, not on therapeutic instructions or benefits.


Official Adverse Reaction Classification

Adverse reactions are classified by frequency, with the most common events typically affecting the respiratory and musculoskeletal systems:

Frequency Tier Example Adverse Reactions (System-Organ Class)
Very Common Nasopharyngitis (Infections and Infestations)
Common Headache, Myalgia (muscle pain), Back Pain, Nausea, Diarrhea (Nervous, Musculoskeletal, and Gastrointestinal Disorders)
Uncommon Hepatitis, Peripheral Neuropathy, Hypoglycemia (Hepato-biliary, Nervous, and Metabolism Disorders)
Rare Rhabdomyolysis, Myopathy, Severe Skin Reactions (SJS/TEN) (Musculoskeletal and Skin Disorders)

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights specific, though rare, serious adverse reactions. The most critical concerns relate to muscle toxicity, including rhabdomyolysis (severe muscle breakdown), which can lead to complications such as acute renal failure, and serious liver injury, including fatal and non-fatal hepatic failure. Liver enzyme abnormalities (transaminases) have been documented to typically occur within the first 12 weeks of treatment.

Use is contraindicated in patients with active liver disease or unexplained, persistent elevations in liver enzymes. Furthermore, the medicine is contraindicated during pregnancy and breastfeeding. The regulatory label notes that the risk of muscle toxicity is increased when Atorvastatin is co-administered with certain drugs, such as potent CYP3A4 inhibitors.

Overdose and Emergency Response

Overdose and when to seek help

In the event of a suspected or confirmed overdose of Bastatin (Atorvastatin), immediate medical attention must be sought. Official regulatory guidance mandates contacting emergency services to initiate management.


Official Regulatory Summary

Feature Description
Required Emergency Action Seek immediate medical attention.
Severe Outcome Risk Rhabdomyolysis (skeletal muscle breakdown).
Specific Antidote No specific antidote is known.

The official overdose profile is structured around the immediate requirement to seek emergency medical help due to the serious potential complication of rhabdomyolysis. While clinical experience with massive overdose is limited, any observed signs are generally expected to be an exacerbation of the drug’s known effects.

Since regulatory labeling confirms that no specific antidote exists and due to the drug’s high plasma protein binding, procedures such as hemodialysis are not expected to be effective in removing the drug. Consequently, clinical management is restricted to providing symptomatic and supportive treatment. This includes close clinical observation of the patient, with monitoring of creatine kinase (CK) levels required if muscle damage (rhabdomyolysis) is suspected. Treatment protocols are general and supportive across all patient populations.

Therapeutic Uses of Bastatin

What Bastatin Treats: Main Uses and Benefits

Bastatin is commonly used to help manage the underlying factor of elevated blood lipids, which falls under conditions like primary hyperlipidemia and mixed dyslipidemia. The medication is also relevant in conditions involving heightened systemic burden, such as Heterozygous Familial Hypercholesterolemia (HeFH), as a core component of a long-term therapeutic strategy. The medicine is used primarily as an adjunct to diet and lifestyle changes to manage lipids and reduce the risk of major symptomatic events.

A main therapeutic benefit is considered relevant for cardiovascular event prevention. For patients with established heart disease or those at high risk (e.g., with Type 2 Diabetes Mellitus), Bastatin may assist with reducing the likelihood of acute, severe symptomatic crises, including non-fatal heart attack, stroke, and occurrences of angina (chest pain). This support contributes to maintaining vascular health and helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Therapeutic Focus

This medication is primarily used to manage conditions characterized by systemic imbalance (elevated LDL and triglycerides) and is applied in scenarios where additional management of discomfort is required to mitigate the risk of severe, acute symptomatic episodes (e.g., heart attack or stroke).

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Bastatin — official regulatory information

The eligibility profile for Bastatin (Atorvastatin) is strictly defined by mandatory constraints and population thresholds documented in government regulatory sources.


Eligibility scope

Category Regulatory Statement (Strictly Label-Based)
Populations for whom use is allowed Adults with primary or mixed hypercholesterolemia. Pediatric patients aged 10 years and older with Heterozygous or Homozygous Familial Hypercholesterolemia (HeFH, HoFH).
Populations for whom use is not recommended Children younger than 10 years of age (use not established). Women who are breastfeeding (lactation).
Populations for whom use is contraindicated Patients with active liver disease or unexplained persistent elevations of serum transaminases. Patients with known hypersensitivity to the active substance or excipients.
Age-related eligibility rules Use is approved for ages ge 10 years for specific familial conditions. Advanced age (over 65 years) is a factor requiring caution due to increased risk of myopathy.
Condition-specific eligibility rules Use requires caution in patients with a history of liver disease, uncontrolled hypothyroidism, or renal impairment due to their status as risk factors for myopathy.
Pregnancy and lactation eligibility status Pregnancy: Routine use is strongly discouraged, but the absolute contraindication has been removed to allow limited use in very high-risk situations. Lactation: Use is generally not recommended.

Eligibility classifications (high-level)

Category Regulatory Statement (Strictly Label-Based)
Eligibility severity classification Contraindicated (Active liver disease); Not Recommended (Breastfeeding, General use in pregnancy); Not Established (Children under 10 years).
Regulatory basis Official FDA Prescribing Information (PI) and Summary of Product Characteristics (SmPC).

Resulting eligibility structure

Official regulatory documents define eligibility by establishing absolute prohibitions against use in patients with compromised organ status (active liver disease) and immunological incompatibility (hypersensitivity). They set clear age thresholds (minimum 10 years) and mandate caution for populations with pre-existing conditions or physiological states that increase the potential for risk, strictly defining the permitted user population.

What should I know about interactions with other medicines?

️ Interactions with other medicines and products

The official regulatory profile for Bastatin (Atorvastatin) is structured around two main types of clinically significant findings: pharmacokinetic exposure changes and pharmacodynamic risk reinforcement. This information is derived exclusively from government regulatory documentation.

Interaction Scope and Classification

Bastatin is a substrate for the CYP3A4 enzyme and key transporters like OATP1B1 and BCRP. Co-administration with potent inhibitors of these systems, such as Cyclosporine, the antibiotic Clarithromycin, or certain HIV Protease Inhibitors, is documented to significantly increase Atorvastatin plasma concentrations. This exposure alteration is the basis for formal regulatory restrictions.

A formal contraindication is in place for co-administration with the Hepatitis C antivirals glecaprevir/pibrentasvir.

Official Interaction Statements

  • Pharmacodynamic Risk: Interactions with fibrates (e.g., Gemfibrozil), high-dose Niacin, and Colchicine carry an officially stated increased risk of myopathy (muscle toxicity) due to additive effects.
  • Timing Rule: The label requires Rifampin to be administered simultaneously with Bastatin to manage the resulting reduction in drug exposure.
  • Exposure Effects: Atorvastatin has been documented to increase the plasma levels (AUC) of both components of oral contraceptives and of Digoxin.
  • Non-Medicinal Interactions: Consumption of grapefruit juice is restricted because it causes a clinically significant rise in Bastatin plasma concentrations. Increased exposure risk applies to geriatric patients due to naturally higher basal plasma concentrations.

Mechanism of Action

How Bastatin Works: Mechanism of Action

Blocking Cholesterol Production at the Source

Bastatin functions as a selective inhibitor of the enzyme HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase) within the liver. This enzyme catalyzes the primary rate-limiting step of the mevalonate pathway. The binding of Bastatin to the enzyme's active site reduces the liver's capacity for endogenous cholesterol synthesis. This action is the initial step in the drug's physiological cascade, resulting in a decreased amount of internally manufactured cholesterol entering the bloodstream.

Boosting Clearance of Circulating Lipoproteins

The resultant decrease in intracellular cholesterol triggers a cellular feedback loop that increases the number of LDL receptors expressed on the surface of liver cells. This mechanism enables the liver to actively clear more low-density lipoprotein (LDL) particles from the bloodstream, thereby resulting in a reduction in the systemic concentration of circulating cholesterol and shaping the drug's established physiological effect on lipoprotein homeostasis.

Non-Lipid Modulation of Vessel Biology

Beyond its central role in lipid metabolism, Bastatin engages in additional mechanistic activity, referred to as pleiotropic effects. These include the modulation of inflammatory mediators and an influence on the function of the endothelium (the inner lining of blood vessels). This non-lipid modulation impacts the underlying biology of the artery wall and the biological processes within the vascular environment.

Dosage and Administration Information

How to Use Bastatin

Bastatin is administered solely by the oral route, typically supplied as a film-coated tablet in strengths of 10 mg, 20 mg, 40 mg, and 80 mg. The medication is prescribed to be taken once daily. This once-daily schedule offers flexibility, as the tablet may be swallowed whole at any time of the day, either with or without food.

The standard approach for adults managing elevated blood lipids begins with a starting dose of 10 mg or 20 mg per day. The established dose range for chronic therapy extends from 10 mg to a maximum of 80 mg once daily. Dosing adjustments, or titration, are conducted methodically, with reviews of the patient’s lipid levels and subsequent changes occurring at intervals of four weeks or more.

Bastatin treatment is used as an adjunct to a standard cholesterol-lowering diet. For certain populations, specific rules apply: no dosage adjustment is required for patients with renal impairment. In pediatric patients (aged 10 years and older) being treated for Heterozygous Familial Hypercholesterolemia (HeFH), the maximum daily dose is capped at 20 mg. If a dose is missed by a significant time frame, generally considered more than 12 hours, the standard procedure is to skip the missed dose and simply resume the regular schedule the following day, without taking a double dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Bastatin

Evidence for Use in Managing Elevated Blood Lipids

The evidence for Bastatin (Atorvastatin) largely stems from Randomized Controlled Trials (RCTs) that research examined in adults with elevated blood lipids, a condition often called primary hyperlipidemia or mixed dyslipidemia. These studies monitored and measured changes in important biomarkers, specifically Low-Density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol.

The short-term and intermediate trials explored whether administering Bastatin was associated with changes in the measured levels of these fats in the bloodstream, often compared to an inactive treatment or an active comparator. Findings describe patterns observed in the studies where the amount of Bastatin administered was associated with a proportional change in the measured LDL-C levels across the observed groups. This research contributes to understanding the patterns related to systemic imbalance.

Evidence for Preventing Cardiovascular Events (High-Risk Patients)

Bastatin was evaluated in studies exploring the rate of serious events like a heart attack or stroke in two distinct groups: those at high risk who have not yet had an event, and those who have already experienced cardiovascular disease. Large-scale, long-term RCTs were evaluated in adults with pre-existing risk factors, such as Type 2 Diabetes Mellitus.

These studies monitored the incidence of Major Adverse Cardiovascular Events (MACE) and assessed the frequency of non-fatal stroke, non-fatal myocardial infarction, and cardiovascular mortality over periods of several years. Data show patterns related to the rate of these events was observed in the study arms.

Evidence in Special Populations and Uncertainties

Research has explored Bastatin was evaluated in specific populations, notably pediatric patients with Heterozygous Familial Hypercholesterolemia (HeFH). The evidence for this group consists primarily of small-scale, short-term RCTs that was studied for changes in LDL-C and other lipid biomarkers. While studies report short-term changes in biomarkers, the long-term effects are not fully established regarding hard cardiovascular events in children who initiate treatment early. Evidence is limited regarding the full lifespan outcome, and results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Bastatin (FAQ)


Q: Why is Bastatin sometimes prescribed to people without a history of heart problems?

Regulatory documents state that this medicine is approved to reduce the risk of major cardiovascular events, such as heart attack or stroke. This indication applies to adults who have not yet had heart disease but have multiple risk factors (e.g., high LDL cholesterol, age, or diabetes).


Q: Can older adults use Bastatin safely?

Official guidance notes that advanced age (over 65 years) is identified as a risk factor for myopathy, which is muscle toxicity, and caution is advised for this population. However, no dosage adjustment is specifically required solely for age or for patients with only renal impairment.


Q: Is Bastatin safe for people who have diabetes?

Studies and official information indicate that the medicine is used in patients with type 2 diabetes and multiple risk factors to reduce the risk of cardiovascular events. However, regulatory labels include a general warning that statins may be associated with an increase in blood sugar (HbA1c and fasting serum glucose).


Q: Is it normal to feel a bit nauseous when first starting Bastatin?

Nausea is classified as a common side effect in the official adverse reactions list. Patient-focused regulatory information suggests that taking the medicine after a meal or snack may help mitigate digestive discomfort.


Q: Why do some people say Bastatin helps with more than just its primary use?

Beyond its main role in cholesterol lowering, the medicine has non-lipid-lowering actions, sometimes referred to as pleiotropic effects. These actions include modulating inflammatory mediators and influencing the function of the endothelium (the inner lining of blood vessels).


Q: What official body approved Bastatin for use?

The active ingredient, Atorvastatin, has been approved for use by major regulatory bodies globally. These bodies include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Q: How quickly should I expect Bastatin to start working?

Regulatory pharmacokinetic data suggests that steady-state concentrations of the active ingredient are typically reached by the third day of dosing. Clinical therapeutic effects, such as the full cholesterol reduction, are usually assessed by a healthcare provider at intervals of four weeks or more.


Q: Can Bastatin cause hair loss?

Official safety summaries list hair loss (alopecia) as an uncommon adverse reaction. This means the effect is reported to affect less than 1 in 100 people who use the medicine, based on regulatory classification.


Q: Is Bastatin safe to take with common vitamins and supplements?

Official regulatory information advises patients to inform their healthcare provider of all vitamins, herbal remedies, and supplements. Regulatory guidance notes that these substances can affect how the medicine works or may potentially be associated with an increased risk of side effects.


Q: Can Bastatin affect my energy levels?

Feeling unusually tired or physically weak, sometimes referred to as asthenia or malaise, is listed as an uncommon or general adverse reaction in regulatory patient information. If you experience these effects, they are noted in the official safety summary.


Q: What should I do if I feel dizzy while using Bastatin?

Dizziness is listed as a common adverse reaction in official safety summaries. The official guidance recommends seeking immediate medical assistance if dizziness is severe, accompanied by confusion, or if fainting occurs.


Q: Are there any known long-term side effects of Bastatin?

An association with the development of increased blood sugar levels or Type 2 Diabetes has been noted with long-term use. Rare but serious side effects, such as muscle damage or liver injury, can occur at any time during chronic treatment, and the label addresses these risks as part of the safety profile.


Q: Can Bastatin interact with over-the-counter pain relievers?

Official documentation does not provide a specific blanket warning for all over-the-counter (OTC) pain relievers. However, the regulatory label contains a general warning for caution when combining it with drugs that may increase the risk of muscle toxicity (myopathy).


Q: Is there a generic version of Bastatin available?

Yes, the U.S. Food and Drug Administration (FDA) has approved multiple generic versions of the active ingredient, Atorvastatin Calcium Tablets.


Q: How often are blood tests required while taking Bastatin?

Blood tests to check liver function (transaminases) are required before starting the medicine and if symptoms of liver problems occur. Cholesterol levels are also monitored periodically, often beginning after the start of treatment, to assess effectiveness.


Q: Does drinking alcohol affect how Bastatin works?

Official regulatory warnings state that drinking substantial quantities of alcohol regularly can increase the risk of liver problems, which is a known serious adverse reaction. Official guidance contains recommendations to limit or cut down on alcohol consumption.


Q: Can Bastatin cause weight gain or loss?

Changes in body weight have been reported in official adverse reaction summaries. Weight loss is listed with an unknown incidence, and increased weight has also been noted in postmarketing reports.


Q: Can Bastatin interact with herbal products like St. John's Wort?

Yes, the herbal remedy St. John's wort (Hypericum perforatum) is specifically documented in regulatory interaction warnings. It reduces the amount of the active ingredient in the blood, which makes the medicine less effective.


Q: How is Bastatin different from a blood thinner?

The medicine is classified as an HMG-CoA reductase inhibitor, belonging to the statin drug class, and works primarily to lower cholesterol in the liver. It is not classified as a blood thinner, which is a general term for anticoagulant or antiplatelet drugs.


Q: Can I store Bastatin in the bathroom cabinet?

Official storage instructions advise keeping the medicine away from excessive heat and protecting it from moisture. Therefore, storage in a moisture-prone area like a bathroom is generally not recommended, as humidity can compromise the medicine's stability and effectiveness.


Q: What is the half-life of Bastatin?

The mean elimination half-life of the active ingredient in the body is approximately 11 to 24 hours. This relatively long half-life supports the medication's authorized once-daily dosing schedule.


Q: What does the research say about Bastatin's impact on quality of life?

While not listed as a core outcome in regulatory documentation, some clinical research studies have explored the medicine’s impact on quality of life. These studies have noted improvements in certain patient groups beyond the primary cholesterol-lowering effect.

How should Bastatin be stored and disposed of?

How to Store and Dispose of Bastatin (Atorvastatin)

The official labeling for Bastatin (Atorvastatin) tablets defines specific rules for storage, handling, and disposal.

Storage Requirements

Constraint Official Requirement
Temperature Store at controlled room temperature, below 30°C (86°F).
Protection Keep away from excessive heat and protect from moisture.
Packaging Must be kept in the original container and kept tightly closed.
Child Safety Store the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired tablets should be handled according to local pharmaceutical waste guidelines. It is officially advised to use a medicine take-back program if available. The product must not be flushed down the toilet or disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bastatin found in:

A-Z Index: